Login to Your Account

Sunovion seeks to 'elevate' COPD treatment with LAMA candidate

By Marie Powers
Staff Writer

Wednesday, February 25, 2015

Sunovion Pharmaceuticals Inc. moved its nebulized LAMA into phase III development by opening the final two studies in a pivotal program that will collectively enroll about 2,340 adults with moderate to very severe COPD.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription